StockData
Solid Biosciences Inc. logo

Solid Biosciences Inc. (SLDB) company profile

SLDBNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 7/30
$6.23−0.25 (-3.86%)

Close on Nov 17, 2026Market cap $668.01MP/E –Yield –

About Solid Biosciences

Biological Products, (No Diagnostic Substances), SIC 2836

Solid Biosciences Inc. is a life sciences company that develops gene therapies for rare neuromuscular and cardiac diseases. Its research and development efforts focus on gene transfer candidates designed to deliver functional transgenes to treat conditions caused by mutated genes. The company's pipeline includes investigational therapies such as SGT-003 for Duchenne muscular dystrophy, SGT-212 for Friedreich's ataxia, SGT-501 for catecholaminergic polymorphic ventricular tachycardia, and SGT-601 for dilated cardiomyopathy. Because its pipeline remains in development, the company does not currently sell commercial products, and its target end-users are patients suffering from these conditions.

The company's principal executive offices and laboratory spaces are located in Charlestown, Massachusetts. Solid Biosciences operates in the United States and relies on external contract manufacturers to produce its drug candidates. Additionally, the company maintains collaborative and licensing relationships with domestic academic centers and medical organizations, including the Mayo Clinic, the University of Florida, and the University of Washington.

Summary of the business section of Solid Biosciences's latest annual report, written by StockData.

Company profile

Company

Legal name
Solid Biosciences Inc.
Founded
2013
Headquarters
Charlestown, MA
Address
500 Rutherford Avenue, 3rd Floor 02129
Phone
(617) 337-4680
Employees
121, Dec 31, 2025
Industry
Biological Products, (No Diagnostic Substances)
Incorporated in
Delaware
Fiscal year ends
December 31
Auditor
PricewaterhouseCoopers LLP, Boston, Massachusetts

Stock & identifiers

Ticker
SLDB
Exchange
Nasdaq
IPO date
Jan 29, 2018
Shares outstanding
107M, Aug 4, 2026
Public float
$317.70M, Jun 30, 2025
Filer category
Non-accelerated filer<br>Smaller reporting company
Stock splits
1-for-15 reverse, Oct 28, 2022
SEC CIK
1707502
CUSIP
83422E204
ISIN
US83422E2046
FIGI
BBG00JN4FXG8
Share class FIGI
BBG00JN4FXH7
EIN
90-0943402

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
Alexander CumboPresident and CEO, Director235,405
Gabriel BrooksChief Medical Officer97,241
Kevin TanCFO & Treasurer99,422
Jessie HanrahanChief Regulatory Officer74,318
Paul HerzichChief Technology Officer72,638
David T. HowtonChief Operating Officer105,077
Ilan GanotDirector146,165
Ian F. SmithDirector141,585
Clare KahnDirector2,960
Advisors Llc PerceptiveDirector6,749,803
Life Sciences Master Fund Ltd PerceptiveDirector–
Joseph EdelmanDirector11,833,539
Adam Leo StoneDirector0
Sukumar NagendranDirector34,258
Lynne Marie SullivanDirector–
Martin I. FreedDirector53,763
Georgia KerestyDirector–
Perceptive Xontogeny Venture Fund, LPDirector6,833,539

CEO pay and shareholder return

Pay versus performance table from the proxy statement

Fiscal yearCEO total payCEO pay actually paidOther executives (avg)Value of $100 investedPeer group
FY2025$5.22M$7.79M$2.46M$105–
FY2024
Alexander Cumbo
$4.87M$3.45M$2.32M$74–
FY2024
Ilan Ganot
$0$0$2.32M$74–
FY2023
Alexander Cumbo
$918.63K$862.41K$1.18M$114–
FY2023
Ilan Ganot
$0$0$1.18M$114–
FY2022$2.20M$1.63M$1.08M$21–

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

Executive compensation, fiscal 2025

Summary compensation table from the latest proxy statement

ExecutiveSalaryBonusStock awardsOption awardsOtherTotalvs. prior year
Alexander Cumbo
President and Chief Executive Officer
$650.99K$449.18K$2.32M$1.79M$12.60K$5.22M+7%
Gabriel Brooks, M.D.
Chief Medical Officer
$502.16K$259.87K$798.63K$756.79K$10.70K$2.33M+12%
David Tyronne Howton
Chief Operating Officer and Secretary
$513.42K$265.70K$1.00M$796.62K$12.60K$2.59M+1%

Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.

IPO

From the final prospectus (Form 424B4) and the first day of trading

Offering

Type
Initial public offering
Final prospectus filed
Jan 29, 2018
Offer price
$16.00
Securities offered
7,812,500
Gross proceeds
$125.00M
Exchange
Nasdaq
First trading day
Jan 26, 2018
First-day close
$22.62+41.4%
Lock-up ends (est.)
Jul 25, 2018

“The initial public offering price is $16.00 per share.”

Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.

Employees

Headcount reported in annual reports

“As of December 31, 2025, we employed 121 full-time employees, including 89 in research and development and 32 in general and administrative positions, and of which 26 of our employees hold Ph.D.”

Corporate history

Events identified from SEC filings

DateEventDetails
Dec 5, 2022Acquisition / saleCompletion of acquisition or disposition of assets (8-K Item 2.01)
Nov 7, 2022Merger voteDefinitive merger proxy statement
Jun 6, 2022Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Jan 29, 2018IPOInitial public offering priced (424B4 prospectus)
Jan 25, 2018Name changeName changed from Solid Biosciences, LLC to Solid Biosciences Inc.
Jan 22, 2018ListingRegistration of securities on an exchange (Form 8-A)

See a number that looks wrong?